Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Deutsches Krebsforschungszentrum patents (2015 archive)


Recent patent applications related to Deutsches Krebsforschungszentrum. Deutsches Krebsforschungszentrum is listed as an Agent/Assignee. Note: Deutsches Krebsforschungszentrum may have other listings under different names/spellings. We're not affiliated with Deutsches Krebsforschungszentrum, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Deutsches Krebsforschungszentrum-related inventors


12/31/15 / #20150374800

Inhibitors of branched-chain-aminotransferase-1 (bcat1) for the treatment of brain tumors

Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotrans-ferase-1 (bcati) or (b) the expression of the gene encoding bcati for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl)cyclohexaneacetic acid (gabapentin).. ... Deutsches Krebsforschungszentrum

12/17/15 / #20150362489

Receptors of rspo2 and rspo3

The present invention relates to the finding that syndecans (sdc) are receptors of rspondin-2 (rspo2) and rspondin-3 (rspo3). Thus, the present invention relates to the identification of rspo2, rspo3 and/or sdc activity modulators by determining if a test compound has the ability to modulate the binding of an rspo2 and/or rspo3 polypeptide to an sdc polypeptide. ... Deutsches Krebsforschungszentrum

11/05/15 / #20150315659

Circulating mirnas as early detection marker and prognostic marker

Provided is a novel method for the early detection and/or discrimination of cancer and anti-cancer agents for the prevention or early treatment of cancer. In particular, the method relates to the determination of levels of circulating mirnas in breast cancer patients, both primary and metastatic. ... Deutsches Krebsforschungszentrum

09/03/15 / #20150247165

Specific tt virus sequences and chimeric tt virus host cell dna molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

Described are single-stranded new sequences of tt viruses, rearranged ttv sequences and hybrid molecules of a specific tt virus sequence and host cell dna that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.. ... Deutsches Krebsforschungszentrum

08/06/15 / #20150218203

Multiple orthogonal labelling of oligonucleotides

In summary, the present invention concerns a method for multiple orthogonal labelling of oligonucleotides, preferably rna or dna, by simultaneously performing the inverse diels-alder reaction (dainv) and the copper-catalyzed click reaction (cuaac), wherein the method is employed in a single step by just adding the different reaction components together and incubating the aqueous reaction mixture preferably for one hour at room temperature. In detail, the reaction components are one or more n3-modified labels, a copper compound, a stabilizing ligand, a reducing agent and one or more electron-deficient label-modified dienes that are added together with an at least double-modified oligonucleotide having one more nucleotides containing one or more n3-reactive groups and one or more electron-rich dienophiles, wherein a terminal alkyne moiety is preferably used as n3-reactive group(s) and a frans-cyclooctene moiety or norbornene is preferably used as electron-rich dienophile(s), more preferably frans-cyclooctene. ... Deutsches Krebsforschungszentrum

07/23/15 / #20150206613

Leaf assembly for a multi-leaf collimator and multi-leaf collimator

The invention relates to a leaf assembly (102) for a multi-leaf collimator, comprising a leaf frame (104) and a plurality of leaves (106) for shielding beams (108) from a selected area, wherein the leaves (106) are arranged sideways and adjacently in the leaf frame (104) for shielding beams (108) being emitted from a radiation source (110) located above the assembly (102), wherein each leaf (106) is mounted in the leaf frame (104) displaceably in an adjusting direction (112) being oriented perpendicularly related to said beams (108), and wherein the leaf frame (104) provides a linear guidance (114) for each leaf (106) within the adjusting direction (112), being designed in a such a way that the leaf frame (104) is adapted to allow for lateral movement of the leaves (106) superposing said linear guidance (114), thus allowing mutual abutting of the leaves (106). Furthermore, the invention relates to a multi-leaf collimator comprising two leaf assemblies (102) according to the invention, wherein the assemblies (102) are arranged to face each other within the adjusting direction (112). ... Deutsches Krebsforschungszentrum

06/18/15 / #20150168377

Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (tix)

The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded rna. ... Deutsches Krebsforschungszentrum

06/04/15 / #20150152169

Inhibitors of thioredoxin-interacting protein (txnip) for therapy

Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (txnip) or (b) the expression of the gene encoding txnip for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan.. . ... Deutsches Krebsforschungszentrum

04/23/15 / #20150110715

Double-labeled probe for molecular imaging and use thereof

The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (a) at least one motif specifically binding to cell membranes of neoplastic cells; (b) at least one chelator moiety of radiometals; and (c) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kda. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.. ... Deutsches Krebsforschungszentrum

02/19/15 / #20150050279

B-cell receptor complex binding proteins containing t-cell epitopes

The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of cd22, cd19, cd20, and cd21, and b) an immunogenic peptide comprising at least one t-cell epitope for use in vaccination of a subject against b-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same. ... Deutsches Krebsforschungszentrum

01/29/15 / #20150030567

Cancer therapy with a parvovirus combined with an hdac inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (hdaci) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.. . ... Deutsches Krebsforschungszentrum

01/15/15 / #20150018239

Biomarker set for identifying a severe form of cancer

The present invention relates to a method for differentiating between i) a severe form of cancer and ii) a mild form of cancer, comprising a) determining the amounts of gene product of at least the genes coding for ribosomal protein s6 (rps6), nucleoside diphosphate kinase (nme/ndka), and caveolin-1, in a sample from a subject, b) comparing the amounts obtained in step a) to reference amounts, and c) differentiating between a severe form of cancer and a mild form of cancer, wherein an increased amount of products of the genes coding for rps6 and nme/ndka and a decreased amount of product of the gene coding for caveolin-1 are indicative of a severe form of cancer. The invention further relates to the use of antibodies specifically recognizing a polypeptide selected from the list consisting of rps6, nme/ndka, and caveolin-1, for differentiating between a severe form of cancer and a mild form of cancer. ... Deutsches Krebsforschungszentrum

01/08/15 / #20150009558

4pi sted fluorescence light microscope with high three-dimensional spatial resolution

An apparatus forming an area of minimum light intensity enclosed by high light intensity includes two objectives focusing light of opposite directions into a common focal area. Light intensities of a first pair of light beams extinguish each other in a first partial area of the focal area. ... Deutsches Krebsforschungszentrum








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Deutsches Krebsforschungszentrum in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Deutsches Krebsforschungszentrum with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###